Adjuvant therapy for lung neuroendocrine neoplasms.

Stage II AC showed a trend towards worse outcomes with adjuvant therapy with 5-year survival of 81% for observation vs 55% for adjuvant therapy ( P = 0.34), however, without statistical significance potentially owing to the few patients available for analysis.

also in 53,322 other papers

Stage III AC patients trended towards a benefit from adjuvant treatment (5-year OS was 46% for observation vs 54% for adjuvant therapy; P = 0.24); however, this also did not reach statistical significance[ 22 ].

also in 111,027 other papers